Literature DB >> 23063315

Infliximab versus ciclosporin in severe ulcerative colitis.

Barrett G Levesque1, William J Sandborn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23063315     DOI： 10.1016/S0140-6736(12)61259-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  [Ciclosporin or infliximab for severe steroid refractory ulcerative colitis: GETAID study (Group d'Etudes Thérapeutiques des Affections Inflammatoires Digestives)].

Authors:  M Zeitz; S Nitschmann
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

Review 2.  Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.

Authors:  Neeraj Narula; John K Marshall; Jean-Frederic Colombel; Grigorios I Leontiadis; John G Williams; Zack Muqtadir; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2016-02-09       Impact factor: 10.864

3.  Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.

Authors:  Eun Hye Kim; Duk Hwan Kim; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.